A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

NCT01888081 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class

Stopped Protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab)

Conditions

Interventions

Sponsor

Virogen Biotechnology Inc.

Collaborators